Allspring Global Investments
ABUS icon

Allspring Global Investments’s Arbutus Biopharma ABUS Stock Holding History

Allspring Global Investments’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-95
Closed -$218 – 2777
2023
Q2 		$218 Buy
+95
New +$247 ﹤0.01% 2682
2023
Q1 		– Sell
-1,000
Closed -$2.33K – 2759
2022
Q4 		$2.33K Sell
1,000
-22
-2% -$53 ﹤0.01% 2846
2022
Q3 		$1K Hold
1,022
– – ﹤0.01% 2834
2022
Q2 		$2K Sell
1,022
-85,076
-99% -$218K ﹤0.01% 2644
2022
Q1 		$256K Sell
86,098
-8,613
-9% -$26.4K ﹤0.01% 2489
2021
Q4 		$368K Buy
+94,711
New +$368K ﹤0.01% 2424

Other funds holding ABUS

WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Allspring Global Investments's ABUS Position: Q3 2023 in Review

Allspring Global Investments sold out of Arbutus Biopharma (ABUS) in Q3 2023, closing a stake of 95 shares — an estimated $218 sold.

Allspring Global Investments first reported a position in ABUS in Q4 2021 and held it in 6 quarters. The position peaked at $368K in Q4 2021. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2023.

  • Allspring Global Investments reported no remaining Arbutus Biopharma position as of Q3 2023 after selling out during the quarter.
  • Allspring Global Investments sold 95 Arbutus Biopharma shares in Q3 2023, an estimated $218.
  • Allspring Global Investments first reported a position in Arbutus Biopharma in Q4 2021 and held it in 6 quarters.
  • Allspring Global Investments's Arbutus Biopharma position peaked at $368K in Q4 2021.
  • 99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2023.

Based on Allspring Global Investments's 13F filing for Q3 2023, filed 27 Oct 2023.